In contrast, in five samples from patients with secondary-progressive MS (SPMS) with histologically classified chronic lesions, we found CD68+HLA-DR+ infiltrates of varying density, but almost no SIGLEC1 expression (Fig. 2a). Here, CD68 is linked to secondary progressive multiple sclerosis.